Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Ruthenium Complexes Double-Vex Alzheimer’s Peptide

Molecules light up to track amyloid-ß and may disrupt the disease-causing peptide’s aggregation pathway, hinting at a possible drug treatment

by Stephen K. Ritter
July 22, 2013 | A version of this story appeared in Volume 91, Issue 29

[+]Enlarge
Credit: J. Am. Chem. Soc.
This computational model shows how a ruthenium complex binds to amyloid-β. The alignment of the complex’s bulky ligands parallel to the fibril axis (shown in red) could inhibit further amyloid-β aggregation.
This computational model shows how a ruthenium complex binds to amyloid-ß. The complex’s bulky ligands align parallel to the fibril axis shown in red, inhibiting further amyloid-ß aggregation.
Credit: J. Am. Chem. Soc.
This computational model shows how a ruthenium complex binds to amyloid-β. The alignment of the complex’s bulky ligands parallel to the fibril axis (shown in red) could inhibit further amyloid-β aggregation.

Peering inside the brain of a person with Alzheimer’s disease reveals cobwebs of disruptive fibrils made up of aggregated amyloid-β peptide. Some scientists believe the key to treating Alzheimer’s, or even preventing it, is to design molecular probes for real-time monitoring of amyloid-β and to develop drug treatments that block amyloid-β aggregation. In a new development, a team led by Angel A. Martí of Rice University and Rajeev Prabhakar of the University of Miami has uncovered that ruthenium complexes containing bulky aromatic bipyridine and dipyridophenazine ligands can perform both functions. The ruthenium complexes, which are already used in DNA detection, luminesce when they bind amyloid-β, and the researchers propose that their bulk could inhibit aggregate formation (J. Am. Chem. Soc. 2013, DOI: 10.1021/ja404850u). Using experimental and computational techniques, the researchers found that the ruthenium complexes bind to amyloid-β with the bulky ligands aligning parallel to the fibril axis. They note that the parallel binding is unprecedented for the ruthenium complexes, which align perpendicular to the axis of DNA strands. The parallel binding orientation, the researchers believe, could block amyloid aggregation. The finding opens new possibilities for using molecules with extended aromatic systems as agents to tackle Alzheimer’s, they conclude.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.